Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
8.19
-0.51 (-5.86%)
Mar 14, 2025, 1:19 PM EDT - Market open

DAWN Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-95.5-188.92-142.18-70.65-40.51
Upgrade
Depreciation & Amortization
2.030.380.530.20.16
Upgrade
Asset Writedown & Restructuring Costs
553-8-
Upgrade
Loss (Gain) From Sale of Investments
-6.39-10.08-2.03--
Upgrade
Stock-Based Compensation
48.2639.3427.2413.320.53
Upgrade
Other Operating Activities
-108---2.1126.69
Upgrade
Change in Accounts Receivable
-13.88----
Upgrade
Change in Inventory
-3.24----
Upgrade
Change in Accounts Payable
0.692.32-1.481.540.13
Upgrade
Change in Unearned Revenue
4.79----
Upgrade
Change in Other Net Operating Assets
38.137.18.051.15-0.49
Upgrade
Operating Cash Flow
-78.11-146.85-109.87-48.54-13.49
Upgrade
Capital Expenditures
-2.17-0.22-0.03--0.09
Upgrade
Sale (Purchase) of Intangibles
-72.1-3--8-
Upgrade
Investment in Securities
-264.73131.6-255.05--
Upgrade
Other Investing Activities
108----
Upgrade
Investing Cash Flow
-230.99128.38-255.07-8-0.09
Upgrade
Issuance of Common Stock
182.35164165.9167.36-
Upgrade
Other Financing Activities
20.94----
Upgrade
Financing Cash Flow
203.29164165.9297.1229.98
Upgrade
Net Cash Flow
-105.82145.52-199.05240.5816.4
Upgrade
Free Cash Flow
-80.28-147.08-109.9-48.54-13.58
Upgrade
Free Cash Flow Margin
-61.21%----
Upgrade
Free Cash Flow Per Share
-0.86-1.84-1.68-1.31-2.46
Upgrade
Cash Income Tax Paid
1.9----
Upgrade
Levered Free Cash Flow
-133.99-82.72-56.86-37.01-9.6
Upgrade
Unlevered Free Cash Flow
-133.99-82.72-56.86-37.01-9.58
Upgrade
Change in Net Working Capital
-22.66-9.57-7.21-2.941.56
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.